Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients

NCT ID: NCT01645033

Last Updated: 2014-09-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if a computerized version of Cognitive Behavioral Therapy (CBT) can improve high-risk sexual behaviors in patients attending an outpatient methadone treatment clinic. This population is at high risk for contracting and spreading hepatitis and HIV. When added to their treatment as usual (TAU), the CBT session will increase the total exposure of clients to education about how to reduce risky sexual and needle use behaviors and provides real world examples. This study seeks to determine if the use of this CBT program is easily added into the clinical program and if patients are satisfied with its use.

The main hypothesis is that the use of computerized CBT in addition to treatment as usual will improve knowledge and reduce occurrences of unprotected sexual activity. The study will also look at patient and clinic costs related to the CBT intervention, drug use and retention/adherence.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We plan to conduct a randomized pilot trial evaluating the feasibility and promise of computerized CBT as a single module targeting risky sexual behavior in a HIV/Hepatitis C virus(HCV) high risk population. In the context of a drug treatment program, we will randomize 60 methadone maintenance patients to either standard treatment as usual at the program (TAU) or TAU plus the HIV/HCV/STD risk reduction module of CBT4CBT("Stay Safe"). Participants will be assessed at baseline, one month and three month time points. The primary outcome measures will be knowledge regarding risk of infection and transmission of HIV/HCV/STD,self report assessment of risky sexual practices, retention in the study and client satisfaction with the module. Our specific aims are as follows:

1. To determine the feasibility of integrating CBT4CBT/"Stay Safe" into this setting. Feasibility will be determined by completion of assessments at 1 and 3 month time points (retention) and satisfaction ratings by participants randomized to the computer module.
2. Compare knowledge of HIV/HCV/STD transmission and its prevention before and after intervention. This will be assessed by percent correct answers on a quiz administered at each assessment.
3. To evaluate changes in drug and sex risk behaviors by treatment. The primary outcome measure will be number of unprotected sexual encounters on self-assessment instruments for risky sexual behaviors.

We hypothesize that the single session of computer-based CBT will result in reduced risky sexual behaviors and increased knowledge of HIV/HCV/STD transmission with differences in retention by intervention. A successful outcome for this pilot project would result in an effect size of 0.30 or more on outcomes of risk behavior. This intervention will be compared to treatment as usual at the participating site, which currently consists of two group educational sessions on safety regarding risks of HIV/AIDS and hepatitis.

Preliminary Data- The case for computer-based behavioral treatments Computer-assisted therapies offer a relatively novel approach to the dissemination of Evidence Based Therapies (EBT) for behavioral interventions. Existing evidence points to their efficacy and cost-effectiveness. Computer-based interventions offer a number of attractive characteristics for use in primary care and substance treatment settings. Their low cost coupled with high consistency, accessibility and standardization are some associated advantages. Ease of implementation will be critical to reaching patients in remote and rural areas or in small medical offices as primary care providers become a mainstay of substance abuse treatment. Risky sexual behaviors can be targeted without the potential negative associations of face to face behavioral interventions for this highly sensitive domain and thus may be ideally modulated with computer-based therapies. Equivalency to counselor-based education for learning new health behaviors, cost-effectiveness, patient satisfaction and accessibility for illiterate patients are other advantages shown with computer-based therapy.

Computer-based CBT: Carroll et al. at Yale have developed an effective computer-based version of CBT, called "CBT4CBT" and have demonstrated its efficacy in reducing drug use and building coping skills.(38) The program makes extensive use of 'movies' as teaching tools: In each module, the user watches an individual confront a difficult situation relevant to that module's topic; after teaching the key skill through a variety of strategies, the 'movie' repeats but has a different ending because the characters implement the targeted coping skills. In developing CBT4CBT, we sought to develop an engaging version of CBT that could take advantage of the capacity of computer-based learning to convey information via a wide range of media (e.g., text, video, graphics, audio instruction, interactive exercises). The CBT4CBT program is highly user-friendly, requiring no previous experience with computers and minimal use of text-based material (i.e., minimal reading is required), and is highly interactive. In particular, we capitalize on the use of videotaped examples to allow users to actually see examples of individuals utilizing skills and strategies in a range of realistic situations. Viewers are able to watch real-life challenges acted out and safe behaviors modeled, while addressing negative or detrimental thought processes that predispose to unhealthy or risky behavior choices (e.g. making a decision to have sex without a condom). Viewer knowledge base is targeted by didactic portions and role playing is modeled by the actors. The module includes the opportunity for the client to print out and perform 'homework' worksheets, shown to be predictive for successful outcomes in CBT. The module allows for considerable control by the viewer, who can choose the speed of progression through the screens and has the capability to go back to previous screens for reviewing.

Single CBT module application: Our original feasibility, efficacy, durability and cost-effectiveness studies for addictions treatment employed the full version of CBT4CBT, comprised of 7 modules. One independent module focuses entirely on targeting risky sexual and drug use practices (titled "Stay Safe"), but has not been evaluated as an independent module for effects on risk reduction. The "Stay Safe" module was developed by Dr. Kathleen Carroll and her team at Yale in consultation with the Connecticut AIDS Education and Training Center director (Karina Danvers) and others. Its development involved the input of the CBT experts (Dr. Carroll, Dr. Michael Copenhaver), infectious disease specialists and substance abuse treatment patients who volunteered to review the module. Like the substance abuse targeted sections, the script was written to be easily recognizable across many socioeconomic and cultural groups. Professional actors were hired to play the parts of substance users in two separate high risk situations, one sexual and one Intravenous drug use (IDU). Skills are taught with multimedia presentation allowing the user to direct the pace of the module, as well as to view the consequences of various choices during the risky situation. The intervention for the proposed pilot study is this single targeted module, "Stay Safe". The module can be completed on virtually any computer, and thus is ideal for implementation in this, and a wide range of settings. Its expense for clinical use will also be reduced as a result of its brevity. These characteristics will make it easily disseminated, with "real world" applications for settings of substance use treatment and primary care medicine.

Overview: In order to maximize scientific yield from this project, we intentionally designed the study to parallel the landmark Calsyn(5) and Tross(6) randomized trials evaluating effects of the 5-session group CDC behavioral approach for risky sex practices reduction in substance abuse treatment programs. We seek to compare as closely as possible the variable of therapy type (computerized CBT in our study versus group therapy for safer sex skills building in theirs), so we sought to minimize the differences between outcome measures and methods. Use of parallels in design and outcome measures will allow us to 'benchmark' outcomes to reported changes in those studies.

Study Population and Sample: Hartford Dispensary (Hartford, CT) will serve as the site. Drug treatment and medical services are offered on an outpatient basis there. This study will enroll clients undergoing IDU treatment with methadone at the site. These clients come in regularly for scheduled maintenance medication and clinical monitoring as well as standard counseling. Many (roughly 55%) of these patients are already HCV and/or HIV positive and therefore pose a significant risk for the transmission of the virus through routes other than IDU.

Recruitment: Clients will be identified through self-presentation response to advertisements and fliers in the clinic. Drug counseling providers may also ask clients if they are interested in participating in the study. A sample size of 60 (30 patients per group) is feasible and would be sufficient to detect a large effect size on risky sexual behavior of \[Cohen's d= 0.3, (alpha.05, power0.8)\]. This effect size is smaller than that reported for behavioral studies in the literature, but should be sufficient to evaluate feasibility and promise of the proposed intervention in this pilot.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opioid Dependence Hepatitis HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAU plus computerized CBT

Standard treatment (TAU) plus a short session using a computer program containing computerized CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.

Group Type EXPERIMENTAL

computerized Cognitive Behavioral Therapy (CBT)

Intervention Type OTHER

Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.

Treatment as Usual (TAU)

Intervention Type OTHER

This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:

* Teaching about the treatment program
* Teaching important ideas about sexual behaviors risks
* Increasing knowledge about specific sexually transmitted diseases
* Discussions of ways to reduce or minimize spread of diseases related to drug use \[for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)\]

Treatment as Usual (TAU)

This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:

* Teaching about the treatment program
* Teaching important ideas about sexual behaviors risks
* Increasing knowledge about specific sexually transmitted diseases
* Discussions of ways to reduce or minimize spread of diseases related to drug use \[for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)\]

Group Type ACTIVE_COMPARATOR

Treatment as Usual (TAU)

Intervention Type OTHER

This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:

* Teaching about the treatment program
* Teaching important ideas about sexual behaviors risks
* Increasing knowledge about specific sexually transmitted diseases
* Discussions of ways to reduce or minimize spread of diseases related to drug use \[for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)\]

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

computerized Cognitive Behavioral Therapy (CBT)

Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.

Intervention Type OTHER

Treatment as Usual (TAU)

This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:

* Teaching about the treatment program
* Teaching important ideas about sexual behaviors risks
* Increasing knowledge about specific sexually transmitted diseases
* Discussions of ways to reduce or minimize spread of diseases related to drug use \[for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)\]

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* mental capability to complete the study (as determined by MMSE, Mini Mental Status Exam score \>25),
* age 18 or older,
* able to speak, read and understand English,
* actively enrolled in methadone maintenance for intravenous drug use for 30 days or longer;
* had unprotected vaginal or anal intercourse or oral sex within the past 6 months;
* not pregnant or trying to become pregnant.

Exclusion Criteria

* have an untreated bipolar or schizophrenic disorder
* are pregnant (by self-report) or trying to become pregnant (these may unduly influence behaviors of sexual activity)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role collaborator

Yale University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kathleen M Carroll, PhD

Role: PRINCIPAL_INVESTIGATOR

Yale University Department of Psychiatry

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hartford Dispensary

Hartford, Connecticut, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P50DA009241-18

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1111009300

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CBT4CBT for Office Based Buprenorphine
NCT03580902 COMPLETED PHASE1/PHASE2
The Staying Safe Intervention
NCT03418636 UNKNOWN NA
Coaching for HCV and HIV
NCT04314414 COMPLETED NA